GlassScriptPhysician profile
David P Mcelreath
NPI 1811198070
$9,117.63
in general payments reported to CMS, 2019-2025
33 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,847 · 2020: $639 · 2021: $1,362 · 2022: $1,602 · 2023: $1,224 · 2024: $1,085 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,640 · Education: $27.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,639.63 |
| Education | $27.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,654.21 | 2019-2025 | |
| Janssen Biotech, INC. | $1,165.98 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $468.76 | 2019-2024 | Entyvio, Gattex |
| Pfizer INC. | $450.42 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $423.90 | 2019-2023 | Trulance |
| Celgene Corporation | $230.96 | 2021-2024 | Zeposia |
| Alkermes, INC. | $198.48 | 2019 | |
| Merck Sharp & Dohme LLC | $173.73 | 2019-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $129.50 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $124.97 | 2024-2025 | Zenpep |
| Janssen Scientific Affairs, LLC | $104.71 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $103.23 | 2022-2025 | Dupixent |
| Alexion Pharmaceuticals, INC. | $99.08 | 2019 | |
| Allergan, INC. | $95.03 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $92.91 | 2024-2025 | Iqirvo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $55.62 | 2024-2025 | |
| Redhill Biopharma INC. | $50.98 | 2020-2021 | |
| Amgen INC. | $50.14 | 2024-2025 | Uplizna |
| Nestle Healthcare Nutrition INC. | $44.30 | 2020-2023 | |
| Celltrion USA INC. | $41.52 | 2024 | Zymfentra, Vegzelma |
| Genzyme Corporation | $39.53 | 2019-2021 | |
| Medtronic USA, INC. | $39.26 | 2020 | |
| Qol Medical, LLC | $38.76 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $34.75 | 2019-2020 | |
| Organon LLC | $31.50 | 2023-2024 | Hadlima |
| Ucb, INC. | $30.16 | 2019-2020 | |
| Ardelyx, INC. | $29.19 | 2023-2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $24.85 | 2022 | |
| Medtronic, INC. | $21.89 | 2025 | Interstim |
| Covidien LP | $21.18 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.03 | 2019 | |
| Evoke Pharma, INC. | $16.70 | 2021 | |
| Olympus America INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mcelreath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.